ロード中...
Real‐life long‐term effectiveness of fingolimod in Swiss patients with relapsing‐remitting multiple sclerosis
BACKGROUND AND PURPOSE: In 2011, fingolimod was approved in Switzerland for the treatment of relapsing‐remitting multiple sclerosis (RRMS). The aim of the present study was to assess the effectiveness and retention of fingolimod in a real‐life Swiss setting, in which patients can receive fingolimod...
保存先:
| 出版年: | Eur J Neurol |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5969089/ https://ncbi.nlm.nih.gov/pubmed/29431876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ene.13594 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|